For over three decades, Liu Li Ping has been racing against stroke. She led the landmark “CHANCE” clinical trial—the first from China published in The New England Journal of Medicine—reducing patients’ 90-day recurrence rate from 11.7% to 8.2%, and further down to 6% in subsequent studies, rewriting global treatment guidelines and saving millions of lives. Her team developed domestically produced thrombolytic drugs, ending reliance on expensive imports, and combined them with AI imaging systems to cut treat ...